| abstract |
An antibody-drug conjugate (ADC) based on an antibody that binds human AXL for use in the treatment of cancer, and a pharmaceutical composition comprising the ADC, the treatment comprising a weekly dose of about 0.45 mg / kg to about 2.0 mg / kg of the ADC once weekly for 3 consecutive weeks, followed by a 1 week washout period in which no ADC is administered, with each cycle period It is 28 days including the period. |